ETPrime

Sun Pharmaceutical Industries Share Price

  • 1,809.6018.65 (1.05%)
  • Volume: 16,44,075
  • Closed
  • Last Updated On: 08 Nov, 2024, 03:55 PM IST
STOCK SCORE
ETPrime Only
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...

Sun Pharmaceutical Industries Share Price

  • 1,809.6018.65 (1.05%)
  • Volume: 16,44,075
Advertisment

Sun Pharma share price insights

View All

  • Company delivered ROE of 15.04% in year ending Mar 31, 2024 outperforming its 5 year avg. of 10.79%. (Source: Consolidated Financials)

  • Company has spent less than 1% of its operating revenues towards interest expenses and 19.44% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

  • Stock gave a 3 year return of 126.2% as compared to Nifty 100 which gave a return of 37.06%. (as of last trading session)

  • Stock generated 126.2% return as compared to Nifty Pharma which gave investors 62.63% return over 3 year time period. (as of last trading session)

  • Sun Pharmaceutical Industries Ltd. share price moved up by 1.05% from its previous close of Rs 1,790.95. Sun Pharmaceutical Industries Ltd. stock last traded price is 1,809.60

    Share PriceValue
    Today/Current/Last1,809.60
    Previous Day1,790.951,791.50

InsightsSun Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		39.28
    EPS - TTM
    (₹)    		46.07
    MCap
    (₹ Cr.)    		4,34,183
    Sectoral MCap Rank
    		1
    PB Ratio
    (x)    		6.40
    Div Yield
    (%)    		0.75
    Face Value
    (₹)    		1.00
    Beta

    Beta

    1 Month0.00
    3 Months0.76
    6 Months0.92
    1 Year0.87
    3 Years0.92

    		0.00
    VWAP
    (₹)    		1,804.11
    52W H/L
    (₹)
    1,960.35 / 1,166.85

    Sun Pharma Share Price Returns

    1 Day1.05%
    1 Week-2.63%
    1 Month-5.61%
    3 Months4.18%
    1 Year53.79%
    3 Years126.2%
    5 Years328.71%

    ET Stock ScreenersTop Score Companies

    Check whether Sun Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Sun Pharma News & Analysis

    View all Sun Pharma Share News & Announcements

    Sun Pharma Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    Sun Pharma Share Recommendations

    Recent Recos

    BUY

    Current

    Mean Recos by 33 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹2280
    • OrganizationMotilal Oswal Financial Services
    • BUY
    • Target₹1995
    • OrganizationJM Financial
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy101089
    Buy12121512
    Hold8888
    Sell3312
    Strong Sell----
    # Analysts33333231
    View all Stock Recommendations

    Sun Pharma Financials

    • Insights

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 19.44% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
      Quarterly | AnnualSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
      Total Income13,645.3913,185.3012,588.8412,630.9012,486.02
      Total Income Growth (%)3.494.74-0.331.162.81
      Total Expenses9,978.349,700.269,699.759,595.829,645.85
      Total Expenses Growth (%)2.870.011.08-0.520.65
      EBIT3,667.053,485.042,889.093,035.082,840.17
      EBIT Growth (%)5.2220.63-4.816.8610.86
      Profit after Tax (PAT)3,040.162,835.622,654.582,523.752,375.51
      PAT Growth (%)7.216.825.186.2417.45
      EBIT Margin (%)26.8726.4322.9524.0322.75
      Net Profit Margin (%)22.2821.5121.0919.9819.03
      Basic EPS (₹)12.7011.8011.1010.509.90
      Quarterly | AnnualSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
      Total Income5,214.014,580.815,758.025,150.555,202.75
      Total Income Growth (%)13.82-20.4411.79-1.0012.38
      Total Expenses4,074.624,106.814,138.654,184.164,102.60
      Total Expenses Growth (%)-0.78-0.77-1.091.990.51
      EBIT1,139.39474.001,619.37966.391,100.15
      EBIT Growth (%)140.38-70.7367.57-12.16100.82
      Profit after Tax (PAT)863.29237.82867.60721.31888.63
      PAT Growth (%)263.00-72.5920.28-18.83133.46
      EBIT Margin (%)21.8510.3528.1218.7621.15
      Net Profit Margin (%)16.565.1915.0714.0017.08
      Basic EPS (₹)3.601.003.603.003.70
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue49,851.0444,520.2039,576.0034,333.6633,473.48
      Total Revenue Growth (%)11.9712.4915.272.5711.24
      Total Expenses38,268.8334,940.3230,527.8627,228.1528,203.25
      Total Expenses Growth (%)9.5314.4512.12-3.4612.51
      Profit after Tax (PAT)9,576.388,473.583,272.732,903.823,764.93
      PAT Growth (%)13.01158.9112.70-22.8741.25
      Operating Profit Margin (%)24.3722.2223.7321.6316.97
      Net Profit Margin (%)19.7419.308.468.6611.46
      Basic EPS (₹)39.9035.3013.6012.1015.70
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue20,740.9321,091.1716,543.9012,953.4314,042.85
      Total Revenue Growth (%)-1.6627.4927.72-7.7621.32
      Total Expenses17,072.2616,412.3314,416.5110,711.0010,789.85
      Total Expenses Growth (%)4.0213.8434.60-0.7311.92
      Profit after Tax (PAT)2,858.181,690.72-99.992,139.703,211.14
      PAT Growth (%)69.05--104.67-33.37293.23
      Operating Profit Margin (%)21.9624.7516.1319.5229.21
      Net Profit Margin (%)14.098.12-0.6416.7125.62
      Basic EPS (₹)11.907.00-0.408.9213.40

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets85,462.8880,743.5969,799.8767,666.7368,252.46
      Total Assets Growth (%)5.8415.683.15-0.865.50
      Total Liabilities18,356.9121,428.1218,733.7618,186.9019,127.77
      Total Liabilities Growth (%)-14.3314.383.01-4.92-4.22
      Total Equity67,105.9759,315.4751,066.1149,479.8349,124.69
      Total Equity Growth (%)13.1316.153.210.729.84
      Current Ratio (x)2.562.002.041.892.02
      Total Debt to Equity (x)0.040.110.020.070.17
      Contingent Liabilities6,343.607,903.076,756.557,057.737,508.95
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets41,064.7940,987.4940,765.4838,998.8338,410.33
      Total Assets Growth (%)0.190.544.531.531.85
      Total Liabilities17,370.3917,239.1316,177.5313,958.6714,014.11
      Total Liabilities Growth (%)0.766.5615.90-0.40-5.76
      Total Equity23,694.4023,748.3624,587.9525,040.1624,396.22
      Total Equity Growth (%)-0.23-3.41-1.812.646.80
      Current Ratio (x)3.361.970.961.451.07
      Total Debt to Equity (x)0.470.320.200.260.24
      Contingent Liabilities2,013.744,309.603,811.823,564.253,863.62

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Decrease in Cash from Investing

        Company has used Rs 690.2 cr for investing activities which is an YoY decrease of 91.31%. (Source: Consolidated Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities12,134.984,959.338,984.546,170.376,554.77
      Net Cash used in Investing Activities-690.20-7,943.68-5,724.74536.22-2,588.84
      Net Cash flow from Financing Activities-6,710.162,376.07-5,193.46-5,980.48-5,715.14
      Net Cash Flow4,661.92115.48-1,764.78596.42-1,385.69
      Closing Cash & Cash Equivalent9,285.654,623.734,508.256,273.035,676.61
      Closing Cash & Cash Equivalent Growth (%)100.832.56-28.1310.51-19.62
      Total Debt/ CFO (x)0.231.250.100.541.16
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities-292.42507.087,636.361,737.251,305.85
      Net Cash used in Investing Activities-262.91-705.17-2,702.10-601.801,479.29
      Net Cash flow from Financing Activities473.95169.31-4,870.85-1,126.29-2,871.15
      Net Cash Flow-83.82-9.2568.471.84-82.26
      Closing Cash & Cash Equivalent326.46410.28419.53222.34220.50
      Closing Cash & Cash Equivalent Growth (%)-20.43-2.2088.690.83-27.17
      Total Debt/ CFO (x)-37.7814.970.643.734.40

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • ROE Outperforming 5 Year Average

        Company delivered ROE of 15.04% in year ending Mar 31, 2024 outperforming its 5 year avg. of 10.79%. (Source: Consolidated Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)15.0415.136.816.248.31
      Return on Capital Employed (%)17.2616.0217.4414.0610.60
      Return on Assets (%)11.2010.494.684.295.51
      Interest Coverage Ratio (x)60.2971.4088.8865.9525.19
      Asset Turnover Ratio (x)0.580.580.560.490.49
      Price to Earnings (x)40.6527.8667.1149.5022.47
      Price to Book (x)6.114.214.573.091.87
      EV/EBITDA (x)26.7519.5119.3015.3611.73
      EBITDA Margin (%)29.6427.9829.2827.8423.22
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)12.067.11-0.408.5413.16
      Return on Capital Employed (%)12.1515.798.208.1513.45
      Return on Assets (%)6.964.12-0.245.488.36
      Interest Coverage Ratio (x)7.7214.309.9612.0110.35
      Asset Turnover Ratio (x)0.490.510.390.330.33
      Price to Earnings (x)136.99140.85-2,500.0067.1126.32
      Price to Book (x)16.419.938.935.733.46
      EV/EBITDA (x)66.0036.0057.9048.4921.22
      EBITDA Margin (%)29.8532.4424.8024.1033.69

    • MANAGEMENT DISCUSSION AND ANALYSIS (FY 19-20)

      • Digital technologies - In post covid world, will it or will it not

        Digital technologies are being leveraged significantly for patient-to-doctor connect currently since a face-to-face consultation may not be possible due to COVID-19. It remains to be seen if this trend will continue in the post COVID-19 period also.

      • Increasing overall market size but pricing pressure might continue

        Pharmaceutical spending in the top five Western European (WE5) markets is projected to grow at about 3-6% CAGR to US$210-240 Billion by 2024. Launch of new-age specialty products will drive this growth. Government led price control initiatives to improve patient access is likely to act as a counter-balancing force to this growth.

      • Indian pharma industry has some inherent strength

        India is uniquely positioned as a crucial supplier of pharmaceuticals by way of chemistry expertise, lower personnel costs and the ability to manufacture quality medicines in compliance with global regulatory standards. It will continue to be an important player in the global generics market.

    Financial InsightsSun Pharma

    • Income (P&L)
    • Cash Flow
    • Ratios

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 19.44% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

      • Decrease in Cash from Investing

        Company has used Rs 690.2 cr for investing activities which is an YoY decrease of 91.31%. (Source: Consolidated Financials)

      • ROE Outperforming 5 Year Average

        Company delivered ROE of 15.04% in year ending Mar 31, 2024 outperforming its 5 year avg. of 10.79%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Sun Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Sun Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Sun Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Sun Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Sun Pharma Technicals

    • Stock doesn't have any Buy/Sell Signals.

    • 47%
      Positive Movement since
      1st Jan 2005 on basis
      53%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic1819.451829.301853.401805.201795.351781.101757.00

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR45.9742.5238.22

    Sun Pharma Peer Comparison

      • CHART
      • TABLE

      Insights

      • Stock Returns vs Nifty 100

        Stock gave a 3 year return of 126.2% as compared to Nifty 100 which gave a return of 37.06%. (as of last trading session)

      • Stock Returns vs Nifty Pharma

        Stock generated 126.2% return as compared to Nifty Pharma which gave investors 62.63% return over 3 year time period. (as of last trading session)

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Insights

          • Stock Returns vs Nifty 100

            Stock gave a 3 year return of 126.2% as compared to Nifty 100 which gave a return of 37.06%. (as of last trading session)

          • Stock Returns vs Nifty Pharma

            Stock generated 126.2% return as compared to Nifty Pharma which gave investors 62.63% return over 3 year time period. (as of last trading session)

          Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Sun Pharma39.286.4715.0417.2611.2013.1024.3719.8939.902.560.040.23
          Divis Labs94.3511.6411.7815.2610.345.1327.6020.3960.277.570.000.00
          Cipla28.744.8015.4321.7912.5910.8223.2216.1251.053.710.010.06
          Torrent Pharma60.1015.8024.1527.1610.9910.0824.3915.4448.941.030.571.21
          Dr. Reddys20.063.7919.7425.1314.3514.1826.2619.86335.222.590.060.36
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Mankind Pharma
          • Cadila Healthcare
          • Lupin
          • Aurobindo Pharma
          • Alkem Labs

          Choose from Stocks

            See All Parameters

          Peers InsightsSun Pharma

          • Stock Returns vs Nifty 100

            Stock gave a 3 year return of 126.2% as compared to Nifty 100 which gave a return of 37.06%. (as of last trading session)

          • Stock Returns vs Nifty Pharma

            Stock generated 126.2% return as compared to Nifty Pharma which gave investors 62.63% return over 3 year time period. (as of last trading session)

          Do you find these insights useful?

          • hate it

          • meh

          • love it

          Sun Pharma Shareholding Pattern

          • Loading...
            Showing Sun Pharma Shareholding as on 30 Sep 2024
            Category30 Sep 202430 Jun 202431 Mar 202431 Dec 2023
            Promoters54.4854.4854.4854.48
            Pledge0.791.072.052.44
            FII18.0017.2317.7217.08
            DII18.4119.0818.6519.35
            Mutual Funds12.1112.7812.2112.93
            Others9.119.219.159.09
          • Showing Shareholding as on 30 Sep 2024
            CategoryNo. of SharesPercentage% Change QoQ
            Promoters1,30,71,34,53554.48 %0.00
            Pledge1,03,90,0000.79 %-0.28
            FII43,23,00,86718.00 %0.77
            DII44,21,41,71918.41 %-0.66
            MF29,06,61,92512.11 %-0.66
            Others21,77,57,8499.11 %-0.09

          Sun Pharma MF Ownership

          MF Ownership as on 30 September 2024

          View all Mutual Fund Schemes
          Top Searches:
          Sun Pharma News Sun Pharma Quarterly Results Sun Pharma Dividend Sun Pharma Q1 ResultsSun Pharma Q2 ResultsSun Pharma Q3 ResultsSun Pharma Q4 Results

          Sun Pharma F&O Quote

            • Expiry

            Price

            1,811.0515.40 (0.86%)

            Open Interest

            1,70,13,85036,400 (0.21%)

            OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
            1,784.451,817.201,784.451,795.655,12532,395.80

            Open Interest as of 08 Nov 2024

          Sun Pharma Corporate Actions

          • Meeting DateAnnounced onPurposeDetails
            Oct 28, 2024Oct 09, 2024Board MeetingQuarterly Results
            Aug 05, 2024Jun 19, 2024AGM-
            Aug 01, 2024Jul 15, 2024Board MeetingQuarterly Results
            May 22, 2024May 13, 2024Board MeetingAudited Results & Final Dividend
            Jan 31, 2024Jan 15, 2024Board MeetingQuarterly Results & Interim Dividend
          • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
            Final500%5.0Jul 12, 2024May 22, 2024
            Interim850%8.5Feb 09, 2024Jan 15, 2024
            Final400%4.0Jul 28, 2023Jul 07, 2023
            Interim750%7.5Feb 08, 2023Jan 16, 2023
            Final300%3.0Aug 19, 2022May 31, 2022
          • All TypesEx-DateRecord DateAnnounced onDetails
            BonusJul 29, 2013Jul 30, 2013May 28, 2013Bonus Ratio: 1 share(s) for every 1 shares held
            SplitsNov 25, 2010Nov 26, 2010Sep 24, 2010Split: Old FV5.0| New FV:1.0
            BonusMay 27, 2004May 29, 2004Apr 21, 2004Bonus Ratio: 1 share(s) for every 1 shares held
            SplitsJan 13, 2003Jan 21, 2003Oct 28, 2002Split: Old FV10.0| New FV:5.0
            BonusMar 06, 2000Mar 23, 2000Feb 09, 2000Bonus Ratio: 2 share(s) for every 1 shares held

          About Sun Pharma

          Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 434,183.66 Crore) operating in Pharmaceuticals sector. Sun Pharmaceutical Industries Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2024. Show More

          • Executives

          • Auditors

          • DS

            Dilip S Shanghvi

            Chairman & Managing Director
            AG

            Abhay Gandhi

            CEO - North America
            SD

            S Damodharan

            CEO - API Business
            UB

            Uday Baldota

            CEO - Taro Pharmaceutical Industries Ltd.
            Show More
          • S R B C & Co. LLP

          Industry

          Pharma - Indian

          Key Indices Listed on

          Nifty 50, BSE Sensex, Nifty 100, + 40 more

          Address

          Sun Pharma Advanced Research Centre (SPARC),Tandalja,Vadodra, Gujarat - 390012

          Contact

          secretarial@sunpharma.com

          http://www.sunpharma.com

          More Details

          FAQs about Sun Pharma share

          • 1. What's Sun Pharma share price today and what are Sun Pharma share returns ?
            Sun Pharma share price was Rs 1,809.60 as on 08 Nov, 2024, 03:55 PM IST. Sun Pharma share price was up by 1.05% based on previous share price of Rs 1,827.45. Sun Pharma share price trend:
            • Last 1 Month: Sun Pharma share price moved down by 5.61%
            • Last 3 Months: Sun Pharma share price moved up by 4.18%
            • Last 12 Months: Sun Pharma share price moved up 53.79%
            • Last 3 Years: Sun Pharma Share price moved up by 126.20%
          • 2. What are the key metrics to analyse Sun Pharma Share Price?
            Sun Pharma share can be quickly analyzed on following metrics:
            • Stock's PE is 39.28
            • Price to Book Ratio of 6.40
          • 3. What is the market cap of Sun Pharma?
            Within the Pharmaceuticals sector, Sun Pharma stock has a market cap rank of 1. Sun Pharma has a market cap of Rs 4,34,184 Cr.
          • 4. Who are the key owners of Sun Pharma stock?
              • Promoter holding has not changed in last 9 months and holds 54.48 stake as on 30 Sep 2024
              • Domestic Institutional Investors holding have gone down from 19.35 (31 Dec 2023) to 18.41 (30 Sep 2024)
              • Foreign Institutional Investors holding has gone up from 17.08 (31 Dec 2023) to 18.0 (30 Sep 2024)
              • Other investor holding has gone up from 9.09 (31 Dec 2023) to 9.11 (30 Sep 2024)
          • 5. What are the returns for Sun Pharma share?
            Return Performance of Sun Pharma Shares:
            • 1 Week: Sun Pharma share price moved down by 2.63%
            • 1 Month: Sun Pharma share price moved down by 5.61%
            • 3 Month: Sun Pharma share price moved up by 4.18%
            • 6 Month: Sun Pharma share price moved up by 18.92%
          • 6. What is the CAGR of Sun Pharma?
            The CAGR of Sun Pharma is 9.69.
          • 7. Which are the key peers to Sun Pharma?
            Top 10 Peers for Sun Pharma are Divi's Laboratories Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Mankind Pharma Ltd., Aurobindo Pharma Ltd., Alkem Laboratories Ltd. and Glenmark Pharmaceuticals Ltd.
          • 8. What has been highest price of Sun Pharma share in last 52 weeks?
            In last 52 weeks Sun Pharma share had a high price of Rs 1,960.35 and low price of Rs 1,166.85
          • 9. Who is the Chief Executive Officer of Sun Pharma?
            Abhay Gandhi is the CEO - North America of Sun Pharma
          • 10. What are the Sun Pharma quarterly results?
            Total Revenue and Earning for Sun Pharma for the year ending 2024-03-31 was Rs 49851.04 Cr and Rs 9576.38 Cr on Consolidated basis. Last Quarter 2024-09-30, Sun Pharma reported an income of Rs 13645.39 Cr and profit of Rs 3040.16 Cr.
          • 11. What is the PE & PB ratio of Sun Pharma?
            The PE ratio of Sun Pharma stands at 38.87, while the PB ratio is 6.4.
          • 12. What dividend is Sun Pharma giving?
            An equity Final dividend of Rs 5 per share was declared by Sun Pharmaceutical Industries Ltd. on 22 May 2024. So, company has declared a dividend of 500% on face value of Rs 1 per share. The ex dividend date was 12 Jul 2024.

          Trending in Markets

          Top Gainers As on 03:59 PM | 08 Nov 2024

          ITI Ltd304.24
          76.36 (33.51%)
          Vijaya Diagnostic1,119.45
          143.55 (14.71%)
          PayTM848.55
          86.70 (11.38%)
          Page Industries48,002.90
          4603.20 (10.61%)
          Dixon Tech15,621.10
          1491.35 (10.55%)

          Top Losers As on 03:59 PM | 08 Nov 2024

          Tube Investments3,890.55
          -583.35 (-13.04%)
          Trent6,298.95
          -850.05 (-11.89%)
          Poly Medicure2,781.00
          -347.90 (-11.12%)
          Triveni Turbine633.45
          -71.85 (-10.19%)
          Brigade Ent.1,124.20
          -127.40 (-10.18%)

          DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

          DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

          By using this site, you agree to the Terms of Service and Privacy Policy.

          Business News›Markets›Stocks›Stock Price Quotes›Sun Pharma Share Price
          The Economic Times
          BrowseCompanies: